Department of Medical and Surgical Sciences Blood Transfusion Center, Azienda Ospedaliera-Università di Padova, Padova, Italy.
Clin Endocrinol (Oxf). 2010 Nov;73(5):630-6. doi: 10.1111/j.1365-2265.2010.03862.x.
To assess autoimmune regulator (AIRE) gene mutations, class II HLA haplotypes, and organ- or non-organ-specific autoantibodies in patients with chronic hypoparathyroidism (CH) without associated Addison's disease (AD) or chronic candidiasis (CC).
DESIGN, PATIENTS AND MEASUREMENTS: Twenty-four patients who had CH without AD or CC were included in the study. AIRE gene mutations in all 14 exons were studied using PCR in 24 patients, 105 healthy controls and 15 first-degree relatives of CH patients with AIRE mutations. Human leucocyte antigens (HLA) were determined for all 24 patients and 105 healthy controls. Autoantibodies to a range of antigens including NACHT leucine-rich-repeat protein-5 (NALP5) and interferon omega (IFNω) were tested in all 24 patients.
AIRE gene mutations were found in 6 of 24 (25%) patients, all females, and this was significantly higher (P < 0·001) compared with AIRE mutations found in healthy controls (2/105). Three patients (12·5%) had homozygous AIRE mutations characteristic of Autoimmune-Poly-Endocrinopathy-Candidiasis-Ectodermal-Dystrophy and all three were also positive for IFNω-autoantibodies. Three patients (12·5%) had heterozygous AIRE mutations; two of these were novel mutations. One of the patients with heterozygous AIRE mutations was positive for both NACHT leucine-rich-repeat protein 5 and IFNω autoantibodies. Heterozygous AIRE mutations were found in 10 of 15 first-degree relatives of CH patients with AIRE mutations, although none was affected by CH. Class II HLA haplotypes were not statistically different in patients with CH compared to healthy controls.
Analysis of AIRE gene mutations together with serum autoantibody profile should be helpful in the assessment of patients with CH, in particular young women with associated autoimmune diseases.
评估无相关艾迪生病(Addison's disease,AD)或慢性念珠菌病(chronic candidiasis,CC)的慢性甲状旁腺功能减退症(chronic hypoparathyroidism,CH)患者的自身免疫调节因子(autoimmune regulator,AIRE)基因突变、Ⅱ类 HLA 单倍型和器官或非器官特异性自身抗体。
设计、患者和测量方法:纳入了 24 例无 AD 或 CC 的 CH 患者。对 24 例患者、105 例健康对照者和 15 例存在 AIRE 基因突变的 CH 患者一级亲属的全部 14 个外显子进行 AIRE 基因突变研究。对所有 24 例患者和 105 例健康对照者进行人类白细胞抗原(human leucocyte antigens,HLA)测定。对所有 24 例患者进行了针对一系列抗原的自身抗体检测,包括 NACHT 亮氨酸丰富重复蛋白-5(NALP5)和干扰素 ω(IFNω)。
发现 24 例患者中有 6 例(25%)存在 AIRE 基因突变,均为女性,明显高于健康对照者中的 AIRE 基因突变(2/105,P < 0·001)。3 例(12·5%)患者存在 Autoimmune-Poly-Endocrinopathy-Candidiasis-Ectodermal-Dystrophy 特征的纯合性 AIRE 基因突变,且均为 IFNω 自身抗体阳性。3 例(12·5%)患者存在杂合性 AIRE 基因突变,其中 2 例是新的突变。存在杂合性 AIRE 基因突变的患者中,有 1 例同时存在 NALP5 和 IFNω 自身抗体阳性。在 15 例存在 AIRE 基因突变的 CH 患者的一级亲属中,发现了 10 例杂合性 AIRE 基因突变,但无一例患有 CH。与健康对照者相比,CH 患者的Ⅱ类 HLA 单倍型无统计学差异。
分析 AIRE 基因突变和血清自身抗体谱有助于评估 CH 患者,特别是伴有自身免疫性疾病的年轻女性。